Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.
Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1110-7. doi: 10.1161/ATVBAHA.109.191601. Epub 2010 May 7.
Cardiovascular disease is the number one cause of death and disability in the US. Understanding the biological activity of stem and progenitor cells, and their ability to contribute to the repair, regeneration and remodeling of the heart and blood vessels affected by pathological processes is an essential part of the paradigm in enabling us to achieve a reduction in related deaths. Both human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells are promising sources of cells for clinical cardiovascular therapies. Additional in vitro studies are needed, however, to understand their relative phenotypes and molecular regulation toward cardiovascular cell fates. Further studies in translational animal models are also needed to gain insights into the potential and function of both human ES- and iPS-derived cardiovascular cells, and enable translation from experimental and preclinical studies to human trials.
心血管疾病是美国头号死亡和致残原因。了解干细胞和祖细胞的生物学活性,以及它们对心脏和血管的修复、再生和重塑的贡献能力,是实现相关死亡率降低这一范例的重要组成部分。人胚胎干细胞(ES)和诱导多能干细胞(iPS)细胞都是有前途的临床心血管治疗细胞来源。然而,需要进一步的体外研究来了解它们向心血管细胞命运的相对表型和分子调控。还需要在转化动物模型中进行进一步的研究,以深入了解人类 ES 和 iPS 衍生的心血管细胞的潜力和功能,并将实验和临床前研究转化为人体试验。